Needham Upgrades Haemonetics to Buy, Announces $112 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has upgraded Haemonetics (NYSE:HAE) from Hold to Buy and set a price target of $112.
June 12, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has upgraded Haemonetics (NYSE:HAE) from Hold to Buy and set a price target of $112.
The upgrade from Hold to Buy and the new price target of $112 by Needham is likely to positively impact Haemonetics' stock price in the short term as it reflects increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100